Krystal Biotech swings to Q4 profit of $8.7 million on $42.1 million VYJUVEK sales
Krystal Biotech reported fourth-quarter and full-year 2023 results, with net product revenue of $42.1 million in the quarter and $50.7 million for the year from VYJUVEK, which was approved in May 2023. The company posted net income of $8.7 million for the quarter versus a $32.1 million loss a year earlier, and $10.9 million for the year, which includes a $100.0 million gain from selling a Priority Review Voucher. The company also gave 2024 non-GAAP R&D and SG&A expense guidance of $150.0 million to $175.0 million.
Key points
- Q4 2023 net product revenue was $42.1 million, versus no product revenue in Q4 2022.
- Q4 2023 net income was $8.7 million ($0.31 per basic share), compared with a loss of $32.1 million in Q4 2022.
- Full-year 2023 net income was $10.9 million, including a $100.0 million gain from the sale of a Priority Review Voucher.
- 2024 non-GAAP combined R&D and SG&A expense guidance is $150.0 million to $175.0 million; cash and investments were $594.1 million at December 31, 2023.
The filing
Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 26, 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.